Accurately Assessing the Expected Impact of Universal First Respiratory Syncytial Virus (RSV) Season Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants
- PMID: 36520978
- DOI: 10.1093/infdis/jiac488
Accurately Assessing the Expected Impact of Universal First Respiratory Syncytial Virus (RSV) Season Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants
Conflict of interest statement
Potential conflicts of interest. The employers of J. F., I. K., and B. R. G. have received payment from AstraZeneca for work on various projects. B. P. has received compensation as advisor/lecturer from AstraZeneca. X. C. E. has received compensation as advisor/lecturer from AstraZeneca and Pfizer. J. E. T. reports no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Comment in
-
Response to Fullarton et al.J Infect Dis. 2023 May 29;227(11):1335-1336. doi: 10.1093/infdis/jiac489. J Infect Dis. 2023. PMID: 36519404 Free PMC article. No abstract available.
Comment on
-
Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model.J Infect Dis. 2022 Aug 15;226(Suppl 2):S282-S292. doi: 10.1093/infdis/jiac216. J Infect Dis. 2022. PMID: 35968866 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources